Durogesic

Fentanyl

Management of chronic & intractable pain in patients requiring continuous opioid administration for an extended period of time.

Individualized based upon the status of the patient & should be assessed at regular intervals after application. Initial dose selection: Appropriate initiating dose should be based on patient's current opioid use. Opioid-naive patient Titrate w/ low dose to attain equianalgesic dose to 25 mcg/hr. May be titrated upward or downward in increments of 12 or 25 mcg/hr. Patch should be replaced every 72 hr. Ped Should be administered only to opioid-tolerant ped patient (2-6 yr) who are already receiving at least 30 mg oral morphine equiv daily.

Hypersensitivity. Management of acute or post-op pain.

Monitor patients who have experienced serious adverse events for at least 24 hr. Do not cut patches. Use only in patients who have demonstrated opioid tolerance. Observe patients for significant resp depression. Patients w/ COPD or other pulmonary disease; susceptible to the intracranial effects of CO₂ eg, those w/ evidence of increased intracranial pressure, impaired consciousness or coma; brain tumors; cardiac disease. Drug dependence may develop upon repeated use. Monitor for signs of misuse, abuse or addiction in patients at increased risk of opioid abuse. Patients w/ fever should be monitored for opioid side effects. Avoid exposing Durogesic to direct external heat sources. Co-administration w/ drugs that affect the serotonergic neurotransmitter systems. May impair ability to drive & use machines. Renal & hepatic impairment. Do not use during pregnancy unless clearly necessary. Not recommended for use in breastfeeding women. Childn <2 yr. Elderly.

Tachycardia; HTN; dyspnoea; dyspepsia.

CNS depressants eg, benzodiazepines & other sedative/hypnotics, opioids, general anesth, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, alcohol & some illegal drugs may increase CNS depressant effects. Increased plasma conc w/ CYP3A4 inhibitors. Decreased plasma conc w/ CYP3A4 inducers. Potentiation of opiate effects w/ MAOIs. Increased risk of serotonin syndrome w/ SSRIs, SNRIs & MAOIs.

Analgesics (Opioid)

N02AB03 - fentanyl ; Belongs to the class of phenylpiperidine derivative opioids. Used to relieve pain.

G